Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses
MWN-AI** Summary
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) faces a class action lawsuit following significant stockholder losses related to alleged misstatements about the company’s CELLECTRA device and its regulatory progress. Robbins LLP has issued a reminder that stockholders who bought Inovio securities between October 10, 2023, and December 26, 2025, may be eligible for recovery.
The suit alleges that Inovio misled investors by failing to disclose deficiencies in manufacturing for its CELLECTRA device, which impacted the timely submission of the biologics license application (BLA) for INO-3107 to the FDA. Initially projected for a mid-2024 submission, the timeline significantly shifted to mid-2025 due to undisclosed manufacturing issues, which was revealed in a press release on August 8, 2024. This announcement led to a 3.1% drop in Inovio's stock price, reflecting investor concerns about the company’s prospects.
Further compounding these issues, a December 29, 2025, announcement disclosed that the FDA would conduct a standard review of INO-3107 rather than an accelerated review, stemming from inadequate information provided by Inovio. This news precipitated a dramatic 24.45% decline in stock price.
Investors affected by these developments are encouraged to act quickly, as the deadline to apply to be a lead plaintiff in the class action is April 7, 2026. Robbins LLP offers representation on a contingency basis, meaning no fees or expenses unless recovery is achieved. The firm is committed to assisting shareholders in recovering losses and promoting accountability within corporate governance. Interested parties can obtain more information by contacting Robbins LLP directly.
MWN-AI** Analysis
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) has recently faced significant challenges that have affected its stock price and investor confidence. Following the company’s disclosure of manufacturing deficiencies related to its CELLECTRA device and delays in the submission of the INO-3107 Biologics License Application (BLA) to the FDA, shareholders have experienced substantial losses. The announcement that the FDA would review INO-3107 under standard rather than accelerated timelines has compounded investor concerns, causing a notable drop in stock price.
As of late December 2025, the stock was trading at $1.73, down from previous highs, indicating a 24.45% decline following the announcement. This presents a precarious situation for current shareholders. For those who have sustained losses, contacting Robbins LLP could provide an avenue for recovery through a class action lawsuit. The firm specializes in shareholder rights and has a history of successfully litigating similar cases.
For potential investors considering entering the Inovio market, it is critical to remain cautious until the company addresses the operational inefficiencies and provides clarity on its regulatory roadmap. Any investment should be predicated on thorough research and an understanding of the biotech sector, which can be notoriously volatile due to the dependency on regulatory approvals.
Moreover, it would be wise to keep an eye on future announcements from Inovio regarding its BLA submission and potential FDA interactions. Clear communication and positive developments regarding its device's manufacturing issues could signify a turn-around, thus presenting an opportunity for patient investors. Until then, caution is advised, and those affected by the stock’s decline should consider their options regarding the class action to potentially recover some of their losses.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus ("HPV").
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is the class period? October 10, 2023 – December 26, 2025
What are the allegations? Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device
According to the complaint, during the class period, defendant failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; and (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.
Plaintiff alleges that on August 8, 2024, Inovio issued a press release reporting its financial results and recent business highlights for the second quarter of 2024, revealing that Inovio expected to submit the INO-3107 BLA to the FDA in mid-2025—representing an approximate full-year delay from defendants' initially projected mid-2024 submission timeline—because of "a manufacturing issue" with a component of the CELLECTRA device. On this news, Inovio's stock price fell $0.27 per share, or 3.1%, to close at $8.44 per share on August 9, 2024.
Then, on December 29, 2025, Inovio issued a press release announcing that the FDA had accepted the INO-3107 BLA on a standard rather than accelerated review timeline. Because the Company did not submit adequate information to justify eligibility for accelerated approval. Defendants further advised that Inovio does not plan to seek approval under the standard review timeline and would request a meeting with the FDA to discuss how it may still pursue accelerated approval. On this news, Inovio's stock price fell $0.56 per share, or 24.45%, to close at $1.73 per share on December 29, 2025.
What can shareholders do now? You may be eligible to participate in the class action against Inovio Pharmaceuticals, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by April 7, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Inovio Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins LLP
FAQ**
What specific details are included in the allegations against Inovio Pharmaceuticals Inc. (INO) regarding the misleading information about the approval for its CELLECTRA device?
How did Inovio Pharmaceuticals Inc. (INO) stock price react following the announcement of delays in submitting the INO-3107 BLA to the FDA in August 2024, and what were the implications for shareholders?
What potential actions can shareholders take now if they purchased Inovio Pharmaceuticals Inc. (INO) securities between October 10, 202and December 26, 2025, considering the ongoing class action lawsuit?
What are the key deadlines for Inovio Pharmaceuticals Inc. (INO) shareholders who want to participate in the class action, and what are the costs associated with hiring Robbins LLP for representation?
**MWN-AI FAQ is based on asking OpenAI questions about Inovio Pharmaceuticals Inc. (NASDAQ: INO).
NASDAQ: INO
INO Trading
-1.42% G/L:
$1.735 Last:
326,364 Volume:
$1.72 Open:
